How much profit has Oncolys Biopharma made this year?
Oncolys Biopharma has made -486.98 M JPY this year.
Oncolys Biopharma Net Income 2024
Oncolys Biopharma Net Income
-486.98 M JPY
Ticker
4588.T
ISIN
JP3202170001
WKN
A1W94N
In 2024, Oncolys Biopharma's profit amounted to -486.98 M JPY, a -74.88% increase from the -1.94 B JPY profit recorded in the previous year.
The Oncolys Biopharma Net Income history
| YEAR | NET INCOME (undefined JPY) |
|---|---|
| 2026e | -999.42 |
| 2025e | -694.18 |
| 2024e | -486.98 |
| 2023 | -1,938.51 |
| 2022 | -1,148.94 |
| 2021 | -1,615.44 |
| 2020 | -2,095.09 |
| 2019 | -912.35 |
| 2018 | -1,233.85 |
| 2017 | -1,090.7 |
| 2016 | -931.4 |
| 2015 | -857.29 |
| 2014 | -739 |
| 2013 | -635.6 |
| 2012 | -102.8 |
| 2011 | 44.9 |
| 2010 | 37.5 |
| 2009 | -906.8 |
| 2008 | -1,615.1 |
Oncolys Biopharma Revenue, EBIT, Net Income JP3202170001 · A1W94N
3 years
5 years
10 years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Oncolys Biopharma, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Oncolys Biopharma from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Oncolys Biopharma’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Oncolys Biopharma. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Oncolys Biopharma’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Oncolys Biopharma’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Oncolys Biopharma’s growth potential.
Oncolys Biopharma Revenue, Profit, and EBIT History
| Date | Oncolys Biopharma Revenue | Oncolys Biopharma EBIT | Oncolys Biopharma Net Income |
|---|---|---|---|
| 2026e | 3.3 B undefined | 0 undefined | -999.42 M undefined |
| 2025e | 1.82 B undefined | 0 undefined | -694.18 M undefined |
| 2024e | 1.01 B undefined | 0 undefined | -486.98 M undefined |
| 2023 | 63.04 M undefined | -1.93 B undefined | -1.94 B undefined |
| 2022 | 976.18 M undefined | -1.2 B undefined | -1.15 B undefined |
| 2021 | 642.49 M undefined | -1.45 B undefined | -1.62 B undefined |
| 2020 | 314.18 M undefined | -1.67 B undefined | -2.1 B undefined |
| 2019 | 1.3 B undefined | -511.46 M undefined | -912.35 M undefined |
| 2018 | 168.55 M undefined | -1.25 B undefined | -1.23 B undefined |
| 2017 | 229.14 M undefined | -1.08 B undefined | -1.09 B undefined |
| 2016 | 178.31 M undefined | -861.31 M undefined | -931.4 M undefined |
| 2015 | 121.3 M undefined | -951.58 M undefined | -857.29 M undefined |
| 2014 | 28.8 M undefined | -827.8 M undefined | -739 M undefined |
| 2013 | 1.2 M undefined | -665.5 M undefined | -635.6 M undefined |
| 2012 | 396.8 M undefined | -141 M undefined | -102.8 M undefined |
| 2011 | 185.8 M undefined | -217.6 M undefined | 44.9 M undefined |
| 2010 | 266.2 M undefined | -130.2 M undefined | 37.5 M undefined |
| 2009 | 67.4 M undefined | -860.5 M undefined | -906.8 M undefined |
| 2008 | 254.6 M undefined | -1.51 B undefined | -1.62 B undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2008 | 254.6 M JPY | -1.51 B JPY | -1.62 B JPY |
| 2009 | 67.4 M JPY | -860.5 M JPY | -906.8 M JPY |
| 2010 | 266.2 M JPY | -130.2 M JPY | 37.5 M JPY |
| 2011 | 185.8 M JPY | -217.6 M JPY | 44.9 M JPY |
| 2012 | 396.8 M JPY | -141 M JPY | -102.8 M JPY |
| 2013 | 1.2 M JPY | -665.5 M JPY | -635.6 M JPY |
| 2014 | 28.8 M JPY | -827.8 M JPY | -739 M JPY |
| 2015 | 121.3 M JPY | -951.58 M JPY | -857.29 M JPY |
| 2016 | 178.31 M JPY | -861.31 M JPY | -931.4 M JPY |
| 2017 | 229.14 M JPY | -1.08 B JPY | -1.09 B JPY |
| 2018 | 168.55 M JPY | -1.25 B JPY | -1.23 B JPY |
| 2019 | 1.3 B JPY | -511.46 M JPY | -912.35 M JPY |
| 2020 | 314.18 M JPY | -1.67 B JPY | -2.1 B JPY |
| 2021 | 642.49 M JPY | -1.45 B JPY | -1.62 B JPY |
| 2022 | 976.18 M JPY | -1.2 B JPY | -1.15 B JPY |
| 2023 | 63.04 M JPY | -1.93 B JPY | -1.94 B JPY |
| 2024e | 1.01 B JPY | 0 JPY | -486.98 M JPY |
| 2025e | 1.82 B JPY | 0 JPY | -694.18 M JPY |
| 2026e | 3.3 B JPY | 0 JPY | -999.42 M JPY |
Oncolys Biopharma stock margins JP3202170001 · A1W94N
The Oncolys Biopharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Oncolys Biopharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Oncolys Biopharma.
3 years
5 years
10 years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Oncolys Biopharma's sales revenue. A higher gross margin percentage indicates that the Oncolys Biopharma retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Oncolys Biopharma's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Oncolys Biopharma's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Oncolys Biopharma's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Oncolys Biopharma. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Oncolys Biopharma's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Oncolys Biopharma Margin History
| Oncolys Biopharma Gross margin | Oncolys Biopharma Profit margin | Oncolys Biopharma EBIT margin | Oncolys Biopharma Profit margin |
|---|---|---|---|
| 2026e | 48.55 % | 0 % | -30.28 % |
| 2025e | 48.55 % | 0 % | -38.21 % |
| 2024e | 48.55 % | 0 % | -48.22 % |
| 2023 | 48.55 % | -3,061.62 % | -3,075.14 % |
| 2022 | 34.67 % | -123.39 % | -117.7 % |
| 2021 | 30.94 % | -226.39 % | -251.43 % |
| 2020 | 75.15 % | -533.02 % | -666.85 % |
| 2019 | 91.34 % | -39.23 % | -69.97 % |
| 2018 | 28.01 % | -740.18 % | -732.04 % |
| 2017 | 68.77 % | -470.63 % | -476 % |
| 2016 | 99.99 % | -483.03 % | -522.34 % |
| 2015 | 99.99 % | -784.46 % | -706.73 % |
| 2014 | 98.61 % | -2,874.31 % | -2,565.97 % |
| 2013 | 91.67 % | -55,458.33 % | -52,966.66 % |
| 2012 | 100 % | -35.53 % | -25.91 % |
| 2011 | 97.9 % | -117.12 % | 24.17 % |
| 2010 | 99.17 % | -48.91 % | 14.09 % |
| 2009 | 59.05 % | -1,276.71 % | -1,345.4 % |
| 2008 | 95.68 % | -591.91 % | -634.37 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2008 | 95.68 % | -591.91 % | -634.37 % |
| 2009 | 59.05 % | -1,276.71 % | -1,345.4 % |
| 2010 | 99.17 % | -48.91 % | 14.09 % |
| 2011 | 97.9 % | -117.12 % | 24.17 % |
| 2012 | 100 % | -35.53 % | -25.91 % |
| 2013 | 91.67 % | -55,458.33 % | -52,966.66 % |
| 2014 | 98.61 % | -2,874.31 % | -2,565.97 % |
| 2015 | 99.99 % | -784.46 % | -706.73 % |
| 2016 | 99.99 % | -483.03 % | -522.34 % |
| 2017 | 68.77 % | -470.63 % | -476 % |
| 2018 | 28.01 % | -740.18 % | -732.04 % |
| 2019 | 91.34 % | -39.23 % | -69.97 % |
| 2020 | 75.15 % | -533.02 % | -666.85 % |
| 2021 | 30.94 % | -226.39 % | -251.43 % |
| 2022 | 34.67 % | -123.39 % | -117.7 % |
| 2023 | 48.55 % | -3,061.62 % | -3,075.14 % |
| 2024e | 48.55 % | 0 % | -48.22 % |
| 2025e | 48.55 % | 0 % | -38.21 % |
| 2026e | 48.55 % | 0 % | -30.28 % |
Oncolys Biopharma Aktienanalyse
What does Oncolys Biopharma do?
Oncolys Biopharma Inc. is a company specialized in the development of innovative medications for the treatment of cancer. The company was founded in 2001 in Tokyo, Japan and has become a key player in the biotechnology industry over the years. The company's business model is based on the development of innovative therapies for cancer patients. It works closely with leading scientists and researchers to advance its research projects, focusing on the discovery and development of new compounds based on the OncoTherad virus. Oncolys Biopharma Inc. offers a wide range of products and services, including cancer medications based on the OncoTherad virus, as well as diagnostic and monitoring tools for hospitals and medical facilities. It has various divisions that encompass research and development, manufacturing, and distribution and marketing of cancer medications and diagnostic systems. The company is committed to expanding its research and development activities to develop new medications for different types of cancer. In addition to cancer medications, Oncolys Biopharma Inc. is also working on developing therapies for other serious illnesses such as viral diseases. The company has a promising pipeline of new medications being tested in various clinical trials. Overall, Oncolys Biopharma Inc. is a key player in the biotechnology industry specializing in the development of innovative therapies for cancer and viral diseases. The company has built an excellent reputation over the years and is committed to continuing its growth and expansion. Oncolys Biopharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding Oncolys Biopharma's Profit Margins
The profit margins of Oncolys Biopharma represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Oncolys Biopharma's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating Oncolys Biopharma's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
Oncolys Biopharma's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When Oncolys Biopharma’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about Oncolys Biopharma Stock
How has the profit developed compared to last year?
The profit has increased by -74.88% compared to last year fallen
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does Oncolys Biopharma publish its earnings?
Oncolys Biopharma publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of Oncolys Biopharma?
The profits of Oncolys Biopharma are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of Oncolys Biopharma?
You can learn more about the earnings of Oncolys Biopharma by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does Oncolys Biopharma pay?
Over the past 12 months, Oncolys Biopharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Oncolys Biopharma is expected to pay a dividend of 0 JPY.
What is the dividend yield of Oncolys Biopharma?
The current dividend yield of Oncolys Biopharma is .
When does Oncolys Biopharma pay dividends?
Oncolys Biopharma pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Oncolys Biopharma?
Oncolys Biopharma paid dividends every year for the past 0 years.
What is the dividend of Oncolys Biopharma?
For the upcoming 12 months, dividends amounting to 0 JPY are expected. This corresponds to a dividend yield of 0 %.
In which sector is Oncolys Biopharma located?
Oncolys Biopharma is assigned to the 'Health' sector.
Wann musste ich die Aktien von Oncolys Biopharma kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Oncolys Biopharma from 6/27/2024 amounting to 0 JPY, you needed to have the stock in your portfolio before the ex-date on 6/27/2024.
When did Oncolys Biopharma pay the last dividend?
The last dividend was paid out on 6/27/2024.
What was the dividend of Oncolys Biopharma in the year 2023?
In the year 2023, Oncolys Biopharma distributed 0 JPY as dividends.
In which currency does Oncolys Biopharma pay out the dividend?
The dividends of Oncolys Biopharma are distributed in JPY.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Oncolys Biopharma
Our stock analysis for Oncolys Biopharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Oncolys Biopharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Oncolys Biopharma Revenue
- Oncolys Biopharma Net Income
- Oncolys Biopharma P/E
- Oncolys Biopharma P/S
- Oncolys Biopharma EBIT
- Oncolys Biopharma Dividend
- Oncolys Biopharma Stocks
- Oncolys Biopharma Market capitalization
- Oncolys Biopharma Debt
- Oncolys Biopharma Liabilities
- Oncolys Biopharma Equity
- Oncolys Biopharma AAQS
- Oncolys Biopharma Employees
- Oncolys Biopharma ROE
- Oncolys Biopharma ROA
- Oncolys Biopharma ROCE
